



- (51) **International Patent Classification:**
A61K 39/215 (2006.01) *C07K 14/165* (2006.01)
A61P 31/14 (2006.01)
- (21) **International Application Number:**
PCT/EP2024/074380
- (22) **International Filing Date:**
30 August 2024 (30.08.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
2313360.6 01 September 2023 (01.09.2023) GB
- (71) **Applicant:** NEC **ONCOIMMUNITY AS** [NO/NO];
Ullernchaaseen 64, 0379 Oslo (NO).
- (72) **Inventors:** **MALONE, Brandon**; NEC OncoImmunity
AS, Ullernchaaseen 64, 0379 Oslo (NO). **GHEORGE,**

Marius; NEC OncoImmunity AS, Ullernchaaseen 64,
0379 Oslo (NO). **CLANCY, Trevor**; NEC OncoImmunity
AS, Ullernchaaseen 64, 0379 Oslo (NO). **STRAT-
FORD, Richard**; NEC OncoImmunity AS, Ullernchaaseen
64, 0379 Oslo (NO). **BENDJAMA, Kaidre**; NEC OncoImmunity
AS, Ullernchaaseen 64, 0379 Oslo (NO).

(74) **Agent:** **GILL JENNINGS & EVERY LLP**, The
Broadgate Tower, 20 Primrose Street, London EC2A 2ES
(GB).

(81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(54) **Title:** T CELL BROAD BETACORONAVIRUS VACCINE




Figure 1

(57) **Abstract:** The present invention relates to polypeptides, polynucleotides, compositions, microorganisms, vectors and vaccine compositions optimised for the treatment or prophylaxis of a disease or infection caused by Betacoronaviruses, including but not limited to: Embecovirus, Hibecovirus, Merbecovirus, Nobecovirus, Sarbecovirus, MERS-CoV, SARS-CoV-1 and SARS-CoV-2. In particular, the invention provides a vaccine composition comprising a polypeptide, wherein the polypeptide comprises one or more epitope sequences, wherein the one or more epitope sequences have the amino acid sequences of any one or more of the sequences of Table 1, or a variant thereof having at least 70% sequence identity thereto, and wherein the polypeptide sequence is no more than 1400 amino acids in length.

[Continued on next page]

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

10 April 2025 (10.04.2025)